BSX Stock Price Today (October 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-10-08
Boston Scientific Corporation (BSX) is trading at $42.04, up 1.11% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $61.00 (45.1% upside).
- Volatility is low (15.73% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.50% YoY) alongside competitive pressures in the Medical Devices space.
BSX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $73.01B
P/E Ratio
Forward P/E: 14.07
Revenue Growth
Year over Year
Analyst Target
+45.1% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 33.56)
- Fundamentals say: Looking solid (debt and growth supportive)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $12.62B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $42.20 and $105.65 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 15.73% annualized volatility and β=0.24, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know
In the closing of the recent trading day, Boston Scientific (BSX) stood at $44.92, denoting a +2.74% move from the preceding trading day.
How Far Can BSX Stock Swing After Losing More Than Half Its Value?
Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.
Cordis wins FDA approval for sirolimus-eluting balloon
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
New Strong Sell Stocks for September 21st
AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.
Boston Scientific (BSX) Stock Trades At A Discount On A 55% Slump
Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...
Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising
Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
Citi downgrades Boston Scientific on uncertain recovery path
Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.
Boston Scientific (BSX) Recalls LUX Dx Cardiac Monitor Over Delayed AF Alerts
Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over atrial fibrillation Burden Alert delays. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring. The US FDA has taken enforcement interest in the action, underscoring regulatory scrutiny of the cardiac monitoring platform and its alert...
Explore More Analysis for BSX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 28, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $42.04. The RSI (14-day) is at 33.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $61.00 implies 45.1% upside from current levels. Volatility is low at 15.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 18.24, which is in line with broader market averages. The forward P/E is 14.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.67, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 2.61. Price-to-Sales is 3.11. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering BSX, the consensus price target is $61.00. This represents a 45.1% upside from the current price of $42.04. The range spans from a low target of $44.00 to a high target of $94.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $12.62B. The debt-to-equity ratio is 0.50x, which is moderate and generally manageable for most companies. The current ratio is 1.24, indicating adequate short-term liquidity. The quick ratio is 0.56. The company holds $539.00M in cash and equivalents. Free cash flow is positive at $2.45B, providing a cushion for debt servicing and shareholder returns.